Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 5:01 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 57 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Neurofibroma, Plexiform Clear all

Conditions: Neurofibromatosis 1, Neurofibroma, Plexiform
Interventions: Medication Event Monitoring System (MEMS^TM), Questionnaires; Behavioral · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 3 Years to 59 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Neurofibromatosis 1, Plexiform Neurofibroma
Interventions: Selumetinib; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 1 Year to 8 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 15
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 11 more

Conditions: Neurofibromatosis Type 1, Plexiform Neurofibroma, Spinal Cord Neurofibroma
Interventions: Cediranib Maleate; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2016
U.S. locations: 9
States / cities: Birmingham, Alabama • Washington D.C., District of Columbia • Chicago, Illinois + 5 more

Conditions: Neurofibromatosis Type 1
Interventions: Selumetinib granule formulation, Selumetinib capsule formulation; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 1 Year to 6 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 4
States / cities: Akron, Ohio • Philadelphia, Pennsylvania • Houston, Texas + 1 more

Conditions: NF type1 With Inoperable Plexiform Neurofibromas
Interventions: Selumetinib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 2 Years to 130 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Neurofibromatosis Type 1 and Growing or Symptomatic, Inoperable PN
Interventions: PD-0325901; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 16 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 11
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Chicago, Illinois + 8 more

Conditions: Neurofibromatosis Type 1, Neurofibromatosis 1, Plexiform Neurofibroma, Plexiform Neurofibromas, Malignant Peripheral Nerve Sheath Tumor, Malignant Peripheral Nerve Sheath Tumors, Atypical Neurofibroma
Interventions: Liquid biopsy for MPNST development; Diagnostic Test
Lead sponsor: David Miller; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Alveolar Soft Part Sarcoma, Angiomatoid Fibrous Histiocytoma, Atypical Fibroxanthoma, Clear Cell Sarcoma of Soft Tissue, Epithelioid Malignant Peripheral Nerve Sheath Tumor, Epithelioid Sarcoma, Extraskeletal Myxoid Chondrosarcoma, Extraskeletal Osteosarcoma, Fibrohistiocytic Neoplasm, Fibrosarcoma, Inflammatory Myofibroblastic Tumor, Intimal Sarcoma, Leiomyosarcoma, Liposarcoma, Liver Embryonal Sarcoma, Low Grade Fibromyxoid Sarcoma, Low Grade Myofibroblastic Sarcoma, Malignant Peripheral Nerve Sheath Tumor, Malignant Skin Granular Cell Tumor, Malignant Triton Tumor, Mesenchymal Chondrosarcoma, Myxofibrosarcoma, Myxoid Chondrosarcoma, Myxoinflammatory Fibroblastic Sarcoma, Nerve Sheath Neoplasm, PEComa, Pericytic Neoplasm, Plexiform Fibrohistiocytic Tumor, Sclerosing Epithelioid Fibrosarcoma, Skin Glomus Tumor, Stage IB Soft Tissue Sarcoma AJCC v7, Stage IIB Soft Tissue Sarcoma AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Synovial Sarcoma, Undifferentiated High Grade Pleomorphic Sarcoma of Bone
Interventions: Doxorubicin, Doxorubicin Hydrochloride, Ifosfamide, Pazopanib, Pazopanib Hydrochloride, Radiation Therapy, Therapeutic Conventional Surgery; Drug · Radiation · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 2 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2026
U.S. locations: 365
States / cities: Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 240 more

Conditions: Neurofibromatosis, Neurofibromas
Interventions: Gleevec; Drug
Lead sponsor: Kent Robertson; Other
Eligibility: 3 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Neurofibromatosis 1
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 7 Years and older
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Neurofibromatosis Type 1, Precancerous Condition
Interventions: Methotrexate, Vinblastine; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: Up to 25 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Neurofibromatosis Type I, Plexiform Neurofibroma
Interventions: Nexavar (BAY 43-9006) (Sorafenib), Toxicity, Pharmacokinetics, Pharmacodynamics, Radiographic Evaluation, QOL assessment, Neuropsychological, Bony Toxicity; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 3 Years to 18 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 2
States / cities: Birmingham, Alabama • Bethesda, Maryland

Conditions: Neurofibromatosis 1, Neurofibroma, Plexiform
Interventions: Pirfenidone; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 3 Years to 21 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 15
States / cities: Birmingham, Alabama • Washington D.C., District of Columbia • Chicago, Illinois + 12 more

Conditions: Neurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PNs), Healthy Participants
Interventions: Treatment A, Treatment B, Treatment C, Treatment D, Acetaminophen; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Neurofibromatosis Type 1, Precancerous Condition
Interventions: fludeoxyglucose F 18, gadopentetate dimeglumine; Radiation
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: Up to 25 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2011
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania

Conditions: Neurofibroma, Plexiform
Interventions: Imatinib Mesylate; Drug
Lead sponsor: Indiana University; Other
Eligibility: 6 Months to 12 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Neurofibromatosis, NF1, Neurofibromas
Interventions: Tasigna; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Neoplasm of Uncertain Malignant Potential, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: PEG-interferon alfa-2a; Biological
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 1 Year to 21 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Chicago, Illinois • Bethesda, Maryland + 1 more

Conditions: Neurofibromatosis 1, Plexiform Neurofibroma, NF1
Interventions: FCN-159; Drug
Lead sponsor: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.; Industry
Eligibility: 2 Years to 70 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 5
States / cities: Los Angeles, California • Gainesville, Florida • St. Petersburg, Florida + 2 more

Conditions: Cancer
Interventions: Trametinib, Dabrafenib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 1 Month to 17 Years
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 10
States / cities: Phoenix, Arizona • San Francisco, California • Washington D.C., District of Columbia + 7 more

Conditions: Neurofibromatosis, MPNST
Interventions: MRI, FDG-PET/CT scans, [18F]-FLT-PET/CT scans; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 10 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Neurofibromatosis 1 (NF1), Plexiform Neurofibromas (PN)
Interventions: Selumetinib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2030
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Neurofibromatosis 1, Plexiform Neurofibroma (PN)
Interventions: Selumetinib, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 4
States / cities: Gainesville, Florida • Rockville, Maryland • St Louis, Missouri + 1 more

Conditions: Neurofibroma
Interventions: LS11; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 3 Years to 21 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

Medication Adherence in Children, Adolescents and Adults With Neurofibromatosis Type 1(NF1) on Clinical Treatment Trials

Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1

AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine

Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PN

An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1

MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1

Neurofibromatosis Type 1 Tumor Early Detection Study

Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery

Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas

Systematically Assessing Changes in Plexiform Neurofibroma Related Disfigurement From Photographs of Subjects With Neurofibromatosis Type 1 on a Phase 2 Clinical Trial

Combination Chemotherapy in Treating Patients With Neurofibromatosis and Progressive Plexiform Neurofibromas

Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas

Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas

A Study to Evaluate Bioavailability and Food Effect of Selumetinib (AZD6244) in Healthy Male Participants

Fludeoxyglucose F 18 Positron Emission Tomography and Magnetic Resonance Perfusion Imaging in Patients With Neurofibromatosis 1 and Plexiform Neurofibroma

Study of Imatinib in Children With Neurofibromatosis and Airway Tumors

Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas

PEG-Interferon Alfa-2b in Treating Young Patients With Plexiform Neurofibroma

Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1

Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations

Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1

MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas

Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas

Phase I Clinical Study of the Safety of Photodynamic Therapy (PDT) Using LS11 in Children With Plexiform Neurofibromas